# Progress Note 02 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Lorraine Hansberry (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML034-SYN
- Date: 2026-05-04
- Fictional facility: St. Posthumous Health Center
- Fictional author: Odette Marchetti-Fields, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Diagnosis visit: biopsy results, the tumor board plan, and the oncology consultation. **S**

## History of present illness

Ms. Hansberry returns two weeks after her first visit. Upper endoscopy two days after that visit found no ulcer but an ulcerated mass in the duodenum next to the papilla, oozing slowly, and the biopsies show adenocarcinoma. The pancreas-protocol CT the next day showed a 3.1 cm mass in the head of the pancreas invading the duodenum, with dilated bile and pancreatic ducts and contact with more than half the circumference of the superior mesenteric vein, but no contact with the arteries and no spread to the liver, peritoneum or lungs. Endoscopic ultrasound a week ago confirmed pancreatic adenocarcinoma on biopsy, and a metal stent was placed in the bile duct at the same session; her urine is lighter and the itching has gone. The tumor board reviewed her five days ago. She had two doses of intravenous iron and has had no more black stools. Pain in the upper abdomen and back is 6 out of 10 and wakes her. Her stools are pale and float after fatty meals. She saw Dr. Adeyemi-Rourke this morning and genetic counseling this afternoon. She asked to be told everything plainly and was. She has had no thoughts of self-harm. **S**

| Element | Detail |
|---|---|
| Diagnosis | Adenocarcinoma of the head of the pancreas invading the duodenum; borderline resectable (venous contact more than 180 degrees, no arterial contact); no distant spread |
| Procedures since the first visit | Upper endoscopy with biopsy; pancreas-protocol CT; EUS-guided biopsy; ERCP with a metal biliary stent; two doses of intravenous iron |
| Tumor board | Modified FOLFIRINOX before surgery, restaging, then resection if no progression |
| Symptoms | Pain 6 out of 10; pale floating stools; no more black stools; itching gone |
| Her questions | Whether this can be cured; whether she can keep writing; what the genetic test means for her family; whether she could still have children |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Tired; weight 55.4 kg, down 0.8 kg in two weeks; no fever |
| Gastrointestinal | Positive | Upper abdominal and back pain; pale, floating stools after fatty meals; no black stools since the iron; nausea mild |
| Integumentary | Negative | Itching gone after the stent; no rash |
| Cardiovascular | Negative | No more near-fainting; no leg swelling |
| Genitourinary | Negative | Urine lighter; last period two weeks ago |
| Psychiatric | Positive | Shaken by the diagnosis and determined; PHQ-9 7, GAD-7 8; no thoughts of self-harm |

6 systems reviewed. **S**

## Current medications

- Pantoprazole 40 mg delayed-release oral tablet, one tablet by mouth once daily before breakfast **S**
- Oxycodone 5 mg oral tablet, one tablet by mouth every 4 hours as needed for pain **S**
- Senna 8.6 mg oral tablet, two tablets by mouth at night while taking oxycodone **S**
- Pancrelipase delayed-release capsule (lipase 36,000 units), two capsules with each meal and one with each snack **S**

## Allergies

- No known allergy **S**

## Objective

BP 108/68 mmHg; pulse 92 bpm; respirations 16/min; temperature 36.7 °C; oxygen saturation 99% on room air; weight 55.4 kg; BMI 20.9 kg/m². All vital signs are synthetic.

Hemoglobin: 10.4 g/dL (low); White cell count: 7 10*3/uL; Absolute neutrophil count: 4.6 10*3/uL; Platelets: 366 10*3/uL; Creatinine: 0.68 mg/dL; eGFR (CKD-EPI 2021): 119 mL/min/1.73 m²; Glucose: 141 mg/dL (high); ALT: 30 U/L; AST: 28 U/L; Alkaline phosphatase: 168 U/L (high); Total bilirubin: 0.9 mg/dL; Albumin: 3.5 g/dL; CA 19-9: 486 U/mL (high); CEA: 3.9 ng/mL (high); INR: 1; PHQ-9: 7; GAD-7: 8; Pain score (0 to 10): 6. All results are synthetic.

## Change since baseline

- Hemoglobin: 9.1 g/dL (low) at baseline, 10.4 g/dL (low) at this visit **S**
- White cell count: 7.4 10*3/uL at baseline, 7 10*3/uL at this visit **S**
- Platelets: 388 10*3/uL at baseline, 366 10*3/uL at this visit **S**
- Creatinine: 0.7 mg/dL at baseline, 0.68 mg/dL at this visit **S**
- eGFR (CKD-EPI 2021): 118 mL/min/1.73 m² at baseline, 119 mL/min/1.73 m² at this visit **S**
- Glucose: 132 mg/dL (high) at baseline, 141 mg/dL (high) at this visit **S**
- ALT: 48 U/L (high) at baseline, 30 U/L at this visit **S**
- AST: 41 U/L (high) at baseline, 28 U/L at this visit **S**
- Alkaline phosphatase: 236 U/L (high) at baseline, 168 U/L (high) at this visit **S**
- Total bilirubin: 1.6 mg/dL (high) at baseline, 0.9 mg/dL at this visit **S**
- Albumin: 3.6 g/dL at baseline, 3.5 g/dL at this visit **S**
- Pain score (0 to 10): 5 at baseline, 6 at this visit **S**

## Immunizations given today

- Pneumococcal conjugate vaccine (PCV20), before chemotherapy **S**
- Recombinant zoster vaccine, dose 1 of 2, before chemotherapy **S**

## Physical examination

| System | Finding |
|---|---|
| General | Thin, tired, composed; weight 55.4 kg; blood pressure 108/68, pulse 92 |
| Eyes | Slight scleral icterus, less than at the first visit |
| Abdomen | Tender in the epigastrium without guarding; no mass felt; no liver enlargement; no ascites |
| Lymph nodes | No supraclavicular nodes; no umbilical nodule |
| Extremities | No calf tenderness or leg swelling |
| Psychiatric | Direct, asks exact questions, writes down the answers; tearful briefly |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Adenocarcinoma of the head of the pancreas, borderline resectable** (C25.0). Pancreatic adenocarcinoma diagnosed two weeks after she first came, because the pain with weight loss, the anemia and the new diabetes were investigated at once rather than put down to stress. It is borderline resectable because of the venous contact, with no arterial involvement and no distant spread. The tumor board and Dr. Adeyemi-Rourke recommend modified FOLFIRINOX before surgery, which she is fit for (ECOG 1, normal kidney and liver function now that the bile is draining), then restaging and resection. CA 19-9 is 486 U/mL, measured after the bilirubin came down so that it reflects the tumor. She was told plainly that the aim is cure, that surgery after chemotherapy offers the best chance, and that the cancer can still return. **S**
   - Port placement next week; cycle 1 of modified FOLFIRINOX in two weeks.
   - Hepatitis B, hepatitis C and HIV tests drawn today; urine pregnancy test negative today.
   - Germline multigene panel sent after counseling; tumor molecular profiling on the EUS cores.
   - PCV20 and the first recombinant zoster vaccine given today, before chemotherapy.
2. **Cancer-related pain** (G89.3). Pain 6 out of 10 from the tumor, breaking her sleep. She wants a clear head for writing, so the plan starts low. **S**
   - Oxycodone 5 mg every 4 hours as needed, with senna.
   - Palliative care consultation in two days.
   - EUS-guided celiac plexus neurolysis if pain becomes severe.
3. **Exocrine pancreatic insufficiency** (K86.81). Pale, floating stools and weight loss from the blocked pancreatic duct; enzyme replacement is started on clinical grounds. **S**
   - Pancrelipase two capsules (72,000 lipase units) with meals and one with snacks.
   - Dietitian review this week.
4. **Diabetes due to the pancreatic cancer** (E08.9). Fasting glucose 141 mg/dL today confirms the A1c of 6.6% from the first visit. This is diabetes caused by the pancreatic disease, not type 2: weight loss and enzyme loss come with it, and insulin, not a drug that causes weight loss, is the treatment if one is needed. **S**
   - Home glucose meter and teaching.
   - No glucose-lowering drug yet.
   - Dexamethasone limited to day 1 of each cycle.
   - Dilated eye examination and urine albumin-to-creatinine ratio to be arranged.
5. **Iron deficiency anemia from blood loss** (D50.0). Hemoglobin up from 9.1 to 10.4 g/dL after two doses of intravenous iron; no bleeding since. **S**
   - Continue pantoprazole.
   - Ferritin with the cycle 4 blood tests.
6. **Epigastric pain with weight loss** (R10.13). Explained by the diagnosis made today; superseded. **S**
   - Problem resolved.
7. **New hyperglycemia** (R73.09). Confirmed as diabetes due to the pancreatic cancer; superseded. **S**
   - Problem resolved.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Tissue diagnosis | Before treatment | Up to date | EUS-guided biopsy: adenocarcinoma of the pancreas, moderately differentiated; duodenal biopsies: adenocarcinoma invading from the pancreas |
| Imaging | Pancreas-protocol CT of the abdomen with CT of the chest | At diagnosis, before any treatment | Up to date | Borderline resectable: superior mesenteric vein contact about 200 degrees with reconstructible narrowing; no arterial contact; no metastases |
| Referral | Pancreatic multidisciplinary tumor board | Before treatment for every localized pancreatic cancer | Up to date | Five days ago: modified FOLFIRINOX first, restaging, then resection |
| Laboratory | Biliary drainage and liver tests | Before chemotherapy when the bile duct is blocked | Completed today | Metal stent placed a week ago; bilirubin 0.9 mg/dL (from 1.6), alkaline phosphatase 168 U/L, ALT 30 U/L, AST 28 U/L, albumin 3.5 g/dL |
| Laboratory | CA 19-9 | At diagnosis after biliary drainage, every two cycles during treatment, before surgery, after surgery, then every three to six months | Completed today | 486 U/mL, drawn after biliary drainage so that it is not falsely raised by jaundice; CEA 3.9 ng/mL |
| Laboratory | Blood count with neutrophils and platelets | Before each chemotherapy cycle and at each visit | Completed today | Hemoglobin 10.4 g/dL, white cells 7.0, neutrophils 4.6, platelets 366 |
| Laboratory | Kidney function before chemotherapy | Before each cycle | Completed today | Creatinine 0.68 mg/dL, eGFR 119 |
| Laboratory | INR before port placement | Before the procedure | Completed today | 1.0 |
| Laboratory | Hepatitis B, hepatitis C and HIV screening | Before chemotherapy | Ordered | Hepatitis B surface antigen, core antibody and surface antibody, hepatitis C antibody and HIV drawn today |
| Laboratory | Pregnancy test | Before chemotherapy | Completed today | Urine pregnancy test negative |
| Referral | Genetic counseling | At diagnosis of pancreatic cancer | Completed today | Pedigree taken; no known pancreatic, breast, ovarian, prostate or colorectal cancer in her family; consent given |
| Laboratory | Germline multigene panel | Once, at diagnosis, for every patient with pancreatic cancer | Ordered | Includes BRCA1, BRCA2, PALB2, ATM, CDKN2A, the Lynch syndrome genes, STK11 and TP53; result in about three weeks |
| Laboratory | Tumor molecular profiling | At diagnosis, on tissue | Ordered | Next-generation sequencing on the EUS cores, with mismatch repair status and fusion testing |
| Referral | Fertility counseling | Before gonadotoxic chemotherapy | Completed today | Oxaliplatin and irinotecan may reduce fertility. Egg or embryo freezing would delay chemotherapy by about two weeks; she chose not to delay treatment, which was respected. Effective non-estrogen contraception advised |
| Referral | Palliative care | From diagnosis, alongside cancer treatment | Referred | Outpatient palliative care consultation in two days |
| Survey | Pain score and opioid review | Each visit | Completed today | Pain 6 out of 10; oxycodone 5 mg as needed started with senna |
| Self-management | Weight, nutrition and enzyme replacement | Each visit | Completed today | Weight 55.4 kg; pancrelipase started; dietitian referral this week |
| Laboratory | Glucose and home readings | Each visit and before each cycle | Completed today | Fasting glucose 141 mg/dL: with the A1c of 6.6%, diabetes is confirmed |
| Examination | Dilated eye examination and urine albumin-to-creatinine ratio | At diagnosis of diabetes, then yearly | Due | To be arranged now that diabetes is confirmed |
| Medication safety | Venous thromboembolism risk (Khorana score) | At the start of chemotherapy | Completed today | Khorana score 3 (pancreatic primary, hemoglobin under 10 g/dL at the first visit). Primary prophylaxis with apixaban is recommended for this score, but it is held for now because the duodenal tumor bled within the last month; to start when there has been no bleeding for several weeks |
| Survey | Distress and depression screen (PHQ-9, GAD-7) | At diagnosis, at each treatment phase, and when symptoms change | Completed today | PHQ-9 7 and GAD-7 8, mild, with fear about the diagnosis; no thoughts of self-harm |
| Self-management | Plain information and support she chooses | At diagnosis and throughout | Completed today | Plain explanation of the diagnosis, its stage and the aim of treatment, with written information; she chose who would be told and who receives her notes |

## Goal progress

- Endoscopy and pancreas-protocol CT within one week, tissue diagnosis and biliary drainage within two weeks, and a tumor board plan within three weeks of presentation. Outcome by 2026-05-04: Endoscopy in two days, CT in three, EUS biopsy and stent in one week, tumor board in nine days, consultation at two weeks. **S**
- Germline genetic testing with counseling and tumor molecular profiling resulted before surgery. In progress; target 2026-06-29. **S**
- Six cycles of modified FOLFIRINOX before surgery with no delay of more than one week. In progress; target 2026-08-10. **S**
- Resection with clear margins if restaging shows no progression. In progress; target 2026-10-05. **S**
- Pain 3 out of 10 or less with a clear head for writing. In progress; target 2026-06-29. **S**
- Weight kept within 5 percent of the weight at diagnosis through chemotherapy, with enzyme replacement and dietitian support. In progress; target 2026-08-10. **S**
- PHQ-9 below 10 throughout treatment, with support she chooses and palliative care alongside cancer treatment. In progress; target 2026-10-05. **S**

## Medication changes

- Started: Oxycodone 5 mg oral tablet, one tablet by mouth every 4 hours as needed for pain **S**
- Started: Senna 8.6 mg oral tablet, two tablets by mouth at night while taking oxycodone **S**
- Started: Pancrelipase delayed-release capsule (lipase 36,000 units), two capsules with each meal and one with each snack **S**

## Guideline basis

- NCCN Clinical Practice Guidelines in Oncology: Pancreatic Adenocarcinoma (2026), National Comprehensive Cancer Network
- Khorana AA, et al. Potentially Curable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2016;34(21):2541-2556 (PMID 27247221) (2016), American Society of Clinical Oncology
- Stoffel EM, et al. Evaluating Susceptibility to Pancreatic Cancer: ASCO Provisional Clinical Opinion. J Clin Oncol 2019;37(2):153-164 (PMID 30457921) (2019), American Society of Clinical Oncology
- Sanders JJ, et al. Palliative Care for Patients With Cancer: ASCO Guideline Update. J Clin Oncol 2024;42(19):2336-2357 (PMID 38748941) (2024), American Society of Clinical Oncology
- Key NS, et al. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Guideline Update. J Clin Oncol 2023;41(16):3063-3071 (PMID 37075273) (2023), American Society of Clinical Oncology
- Hwang JP, et al. Hepatitis B Virus Screening and Management for Patients With Cancer Prior to Therapy: ASCO Provisional Clinical Opinion Update. J Clin Oncol 2020;38(31):3698-3715 (PMID 32716741) (2020), American Society of Clinical Oncology
- Oktay K, et al. Fertility Preservation in Patients With Cancer: ASCO Clinical Practice Guideline Update. J Clin Oncol 2018;36(19):1994-2001 (PMID 29620997) (2018), American Society of Clinical Oncology
- American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes-2026 (classification of diabetes, including diabetes of the exocrine pancreas) (2026), American Diabetes Association
- Noel M, Fiscella K. Disparities in Pancreatic Cancer Treatment and Outcomes. Health Equity 2019;3(1):532-540 (PMID 31663065) (2019), Health Equity (Mary Ann Liebert)
- Depression and Suicide Risk in Adults: Screening (2023), U.S. Preventive Services Task Force

## Follow-up

- Palliative care in two days; port next week; cycle 1 in two weeks. Primary care review at cycle 4. Call at once for fever, yellow eyes, black stools, fainting, or leg swelling. **S**
- Next scheduled visit 2026-06-29: day 1 of cycle 4 of modified FOLFIRINOX: toxicity review, genetic and tumor profiling results, thromboprophylaxis, nutrition and mood. **S**
